D.E. Shaw & Co
ALXO icon

D.E. Shaw & Co’s ALX Oncology ALXO Stock Holding History

D.E. Shaw & Co’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-75,900
Closed -$47.3K – 4324
2025
Q1 		$47.3K Sell
75,900
-179,978
-70% -$216K ﹤0.01% 4067
2024
Q4 		$427K Sell
255,878
-34,518
-12% -$53.1K ﹤0.01% 3714
2024
Q3 		$529K Buy
290,396
+271,456
+1,433% +$1.01M ﹤0.01% 3666
2024
Q2 		$114K Buy
+18,940
New +$233K ﹤0.01% 4148
2024
Q1 		– Sell
-50,178
Closed -$747K – 4311
2023
Q4 		$747K Buy
50,178
+4,496
+10% +$42.7K ﹤0.01% 3320
2023
Q3 		$219K Sell
45,682
-2,525
-5% -$13.7K ﹤0.01% 3730
2023
Q2 		$362K Buy
48,207
+7,132
+17% +$46.7K ﹤0.01% 3541
2023
Q1 		$186K Buy
41,075
+15,152
+58% +$115K ﹤0.01% 3918
2022
Q4 		$292K Buy
25,923
+700
+3% +$7.86K ﹤0.01% 4099
2022
Q3 		$241K Sell
25,223
-9,163
-27% -$107K ﹤0.01% 4394
2022
Q2 		$278K Buy
+34,386
New +$374K ﹤0.01% 4394
2021
Q4 		– Sell
-7,710
Closed -$569K – 5361
2021
Q3 		$569K Sell
7,710
-38,109
-83% -$2.54M ﹤0.01% 4011
2021
Q2 		$2.5M Sell
45,819
-6,439
-12% -$385K ﹤0.01% 2712
2021
Q1 		$3.85M Buy
52,258
+45,423
+665% +$3.57M ﹤0.01% 2053
2020
Q4 		$589K Buy
+6,835
New +$411K ﹤0.01% 3309

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co's ALXO Position: Q2 2025 in Review

D.E. Shaw & Co sold out of ALX Oncology (ALXO) in Q2 2025, closing a stake of 75,900 shares — an estimated $47.3K sold.

D.E. Shaw & Co first reported a position in ALXO in Q4 2020 and held it in 15 quarters. The position peaked at $3.85M in Q1 2021. 61 funds tracked by Wall St. Rank hold ALXO as of Q2 2025.

  • D.E. Shaw & Co reported no remaining ALX Oncology position as of Q2 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 75,900 ALX Oncology shares in Q2 2025, an estimated $47.3K.
  • D.E. Shaw & Co first reported a position in ALX Oncology in Q4 2020 and held it in 15 quarters.
  • D.E. Shaw & Co's ALX Oncology position peaked at $3.85M in Q1 2021.
  • 61 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.